Clinical Trials Sponsored by Gilead Sciences

Total 19394 results

Gilead Sciences

Approved for marketing

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States, Italy, United Kingdom, Ireland
Gilead Sciences

Completed

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Hepatitis C | HIV

Puerto Rico
Gilead Sciences

Completed

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Hepatitis C

United States
Gilead Sciences

Completed

Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE)

Cystic Fibrosis

United States, France, Spain, Germany, Austria, Belgium, Italy, Netherlands, Poland
Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Terminated

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis (ARTEMIS-PH)

Idiopathic Pulmonary Fibrosis | Pulmonary Hypertension

United States, Germany, United Kingdom, Australia, Canada, Italy, Austria
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX1)

Bronchiectasis

United States, Canada, Australia
Gilead Sciences

Terminated

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Chronic Obstructive Pulmonary Disease | Cystic Fibrosis

United States
Gilead Sciences

Completed

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension (Darusentan)

Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, New Zealand
Gilead Sciences

Terminated

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension (Darusentan)

Hypertension

United States, Sweden, Argentina, Denmark, Brazil, Canada, France, United Kingdom
Gilead Sciences

Completed

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

HIV Infections | Renal Impairment | Fanconi Syndrome | Kidney Disease

Canada, United States
Gilead Sciences

Completed

Safety Study of Once a Day ART and Opiate Substitute. (3OD)

HIV Infections

Germany
Gilead Sciences

Completed

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Hepatitis B

Korea, Republic of, United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

Hepatitis B | HBV

Korea, Republic of, United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

HIV-1 Infection

United States
Gilead Sciences

Approved for marketing

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (EAP)

Cystic Fibrosis | Pseudomonas Aeruginosa

Canada
Gilead Sciences

Completed

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Lymphoma, Non-Hodgkin (NHL)

United States
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

Type 2 Diabetes Mellitus

United States
Gilead Sciences

Completed

Open-Label Hepatic Impairment Study

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France
Gilead Sciences

Completed

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Chronic Hepatitis B

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

Pulmonary Hypertension

United States, Canada, Australia
Gilead Sciences

Completed

A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection

Chronic Hepatitis B

United States
Gilead Sciences

Completed

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

Chronic Hepatitis B

France, Germany, United States, Spain
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) (AIR-CF3)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Gilead Sciences

Terminated

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

Febrile Neutropenia

Greece
Gilead Sciences

Completed

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

HIV Infections

United States
Gilead Sciences

Completed

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

Fungus Diseases

Italy
Gilead Sciences

Completed

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Genital Warts

United States
Gilead Sciences

Completed

CRITIC - Treatment of Candidemia and Invasive Candidiasis (CRITIC)

Candidemia | Invasive Candidiasis

Italy
Gilead Sciences

Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections

United Kingdom
Gilead Sciences

Completed

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial (COOL)

HIV Infections

France
Gilead Sciences

Completed

Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.

HIV
Gilead Sciences

Completed

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

HIV Infections

United Kingdom
Gilead Sciences

Completed

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Invasive Aspergillosis | Other Fungal Infections
Gilead Sciences

Recruiting

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Israel
Gilead Sciences

Recruiting

Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus (MARASLE)

Rheumatoid Arthritis | Systemic Lupus Erythematosus

United States, United Kingdom, Georgia, Moldova, Republic of
Gilead Sciences

Recruiting

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

Ulcerative Colitis

United States, Australia, United Kingdom, Korea, Republic of, Japan, Italy, France, Canada, Switzerland, Austria, Germany, Hungary, Poland
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
Gilead Sciences

Recruiting

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Chronic Hepatitis D Infection

United States

3

Subscribe